

### ZIKA VIRUS CASE REPORT FORMS – MATERNAL ACUTE SYMPTOMS – (MAS)





Mother's Identification Code :	Neonate's Identification Code:	
--------------------------------	--------------------------------	--

#### **Introduction**

This standardized Case Report Form (CRF) is the result of an ongoing effort between the World Health Organization (WHO), The Pan-American Health Organization (PAHO), Institute Pasteur (IP), and the networks of ISARIC, CONSISE PREPARE and REACTing to generate standardized clinical and epidemiological research tools.

#### **DESIGN OF THIS CASE REPORT FORM (CRF)**

There are two sets of Case Report Form (CRF) to be used - Neonate and Maternal. The CRFs are to be used in combination for prospective cohort studies or case control studies.

These sets of CRFs are to be used at admission and at discharge/going home. For any patients admitted for more than 24 hours, the Baseline and Outcome CRF and the Laboratory Results CRF can be copied and used for daily data recording.

For all studies, we recommend completing a minimum of the Maternal Baseline and Outcome (MBO) and Neonate Baseline and Outcome (NBO) CRFs, follow by Maternal Laboratory Results (MLR) and Neonate Laboratory Results (NLR) CRFs for all neonates post-delivery. If the mother and/or neonate is admitted to an Intensive Care Unit or Pediatric Intensive Care Unit, complete Maternal Intensive Care (MIC), and/or Neonate Intensive Care (NIC) as well.

For pregnant women presenting with acute symptoms, complete **Maternal Acute Symptoms (MAS)**, and for all studies complete **Maternal Antenatal Care (MAC)**.

Complete the outcomes sections in CRFs MBO and NBO once all diagnostics laboratory results and final diagnosis are available.

#### **HOW TO USE THIS CRF**

When completing the CRF modules, please make sure that:

- The mother or consultee/guardian/representative has been given information about the study and the informed consent form has been completed and signed.
- The study ID codes have been assigned for both mother/pregnant woman and neonate as per hospital protocol and guidelines.
- The study ID codes should be filled in on all pages of paper CRF forms, all information should be kept confidential at all times, and no identifiable information is recorded on the CRFs.
- Patients' hospital ID and contact details are recorded on a separate contact list to allow later follow up. The contact forms must be kept separate from the CRFs at all times and kept in a secure location.

Each site may choose which data to collect based on available resources and the number of patients enrolled to date. Ideally, data on patients (neonate and mother) will be collected using all CRF modules as appropriate.

Sites with very low resources or very high patient numbers may select **Maternal and Neonatal Baseline and Outcome** CRF modules. The decision is up to the Site Investigators and may be changed throughout the data collection period. All high quality data is valuable for analysis.

#### **GENERAL GUIDANCE**

- The CRFs are designed to collect data obtained through patient examination, through parent/guardian/representative (for neonates) interview and review of hospital notes.
- Patient ID codes should be filled in on all pages of paper CRF forms (neonate and mother).
- Complete every line of every section, except for where the instructions say to skip a section based on certain responses.
- Selections with square boxes ( $\square$ ) are single selection answers (choose one answer only). Selections with circles ( $\circ$ ) are multiple selection answers (choose as many answers as are applicable).
- It is important to indicate when the answer to a particular question is not known. Please mark the 'Unknown' box if this is the
- Some sections have open areas where you can write additional information. To permit standardized data entry, please avoid writing additional information outside of these areas.
- We recommend writing clearly in black or blue ink, using BLOCK-CAPITAL LETTERS.
- Place an (X) when you choose the corresponding answer. To make corrections, strike through (----) the data you wish to delete and write the correct data above it. Please initial and date all corrections.
- Please keep all of the sheets for each study subject together e.g. with a staple or in a folder that is unique to the patient.



### ZIKA VIRUS CASE REPORT FORMS -**MATERNAL ACUTE SYMPTOMS – (MAS)**





iviotner's identification Code : Neonate's identification Code :	Mother's Identification Code :	Neonate's Identification Code :
--	--------------------------------	---------------------------------

· Please contact us if we can help with any CRF completion questions, if you have comments and to let us know that you are using the forms. Please contact Dr Gail Carson by email: <a href="mailto:gail.carson@ndm.ox.ac.uk">gail.carson@ndm.ox.ac.uk</a>

Disclaimer: These CRFs are intended for use as a standardized document for the collection of clinical data in studies investigating the Zika virus. Responsibility for use of these CRFs rests with the study investigators. ISARIC and the authors of the CRF accept no responsibility for the use of the CRF in an amended format nor for the use of the standardized CRF outside its intended purpose. Formatting issues are in the process of being resolved. Word documents are available in order to adapt and translate the CRFs, S

1. Geoposition	Latitude:	<b>.</b>		Long	itude:	<b>_•</b>	
2. Name of site/clinic/hospital							
If geoposition not available:	•						
3. City/town/village							
4. Country							
5. Admitted to hospital	☐ Yes ☐ N	No □ U	nknown				
<ol><li>If yes, date of admission (dd/mm/yyyy)</li></ol>	//20	_	7. Date of discharge		_/_/	20 Unknown	
8. Name of hospital admitted to and town/city							
9. Date of onset of first symptoms (dd/mm/yyyy)	_/_/20						
10. Date (dd/mm/yyyy) 11. Maximum Temperature			°C ☐°F ☐ Unknown ☐Oral ☐Tympanic ☐Axillary ☐Anal ☐Skin				
10. Date (dd/mm/yyyy)		/_	/ 20				
11. Maximum Temperature							
42 Barriada Bala		⊔Ora	· · ·		•		
12. Respiratory Rate					minute		
				reaths/		Unknown	
13. Heart Rate			k	eats/mi		□ Unknown	
13. Heart Rate 14. Systolic Blood Pressure			k	eats/mi nmHg		☐ Unknown ☐ Unknown	
13. Heart Rate 14. Systolic Blood Pressure 15. Diastolic Blood Pressure	1		k m	eats/mi nmHg nmHg		☐ Unknown ☐ Unknown ☐ Unknown	
13. Heart Rate 14. Systolic Blood Pressure 15. Diastolic Blood Pressure 16. Peripheral O <sub>2</sub> Saturation (SpO <sub>2</sub>			k 	eats/mi nmHg		☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown	
13. Heart Rate 14. Systolic Blood Pressure 15. Diastolic Blood Pressure 16. Peripheral O <sub>2</sub> Saturation (SpO <sub>2</sub> 17. Glasgow Coma Score (out of 15	i) or		t t 	peats/minmHg nmHg nmHg	nute	☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown	
13. Heart Rate 14. Systolic Blood Pressure 15. Diastolic Blood Pressure 16. Peripheral O <sub>2</sub> Saturation (SpO <sub>2</sub> 17. Glasgow Coma Score (out of 15	i) or	□Ale	t 	neats/minmHg nmHg nmHg 6	nute bal stimuli	☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown	
13. Heart Rate 14. Systolic Blood Pressure 15. Diastolic Blood Pressure 16. Peripheral O <sub>2</sub> Saturation (SpO <sub>2</sub> 17. Glasgow Coma Score (out of 15) 18. AVPU (tick state of consciousne	i) or	□Ale	t m m 9 15 rt □Respond sponds to pain	peats/minmHg nmHg 6 /s to veri	bal stimuli	☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown	
13. Heart Rate 14. Systolic Blood Pressure 15. Diastolic Blood Pressure 16. Peripheral O <sub>2</sub> Saturation (SpO <sub>2</sub> 17. Glasgow Coma Score (out of 15 18. AVPU (tick state of consciousne) 19. Weight	i) or	□Ale	tk 	neats/minmHg nmHg  / / / / / / / / / / / / / / / / / /	bal stimuli	☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown	
13. Heart Rate 14. Systolic Blood Pressure 15. Diastolic Blood Pressure 16. Peripheral O <sub>2</sub> Saturation (SpO <sub>2</sub> 17. Glasgow Coma Score (out of 15 18. AVPU (tick state of consciousne) 19. Weight 20. Height	i) or	□ Ale	t m m 9 15 rt	beats/minmHg nmHg  ks to veristimuli kg	bal stimuli	☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown	
13. Heart Rate 14. Systolic Blood Pressure 15. Diastolic Blood Pressure 16. Peripheral O <sub>2</sub> Saturation (SpO <sub>2</sub> 17. Glasgow Coma Score (out of 15 18. AVPU (tick state of consciousne) 19. Weight 20. Height 21. Weight loss If yes, specify lost during this of	s) or ess)	□ Ale	t m m m f f f f f f f f f f f f f f f f f	beats/minmHg nmHg 6 Is to veristimuli kg	bal stimuli Unrespounds/ou	☐ Unknown	
13. Heart Rate 14. Systolic Blood Pressure 15. Diastolic Blood Pressure 16. Peripheral O <sub>2</sub> Saturation (SpO <sub>2</sub> 17. Glasgow Coma Score (out of 15 18. AVPU (tick state of consciousne) 19. Weight 20. Height 21. Weight loss If yes, specify lost during this of episode of illness	s) or ess)	□ Ale □ Re	tender to the control of the control	beats/minmHg nmHg  kg	bal stimuli Unres counds/our feet/inche	☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ State of the control of the contr	
13. Heart Rate 14. Systolic Blood Pressure 15. Diastolic Blood Pressure 16. Peripheral O <sub>2</sub> Saturation (SpO <sub>2</sub> 17. Glasgow Coma Score (out of 15 18. AVPU (tick state of consciousne) 19. Weight 20. Height 21. Weight loss If yes, specify lost during this of episode of illness 22. Lymphadenopathy	s) or ess)	□ Ale □ Re □ Yes □ □ Cer	tendent depth of the control of the	beats/mi nmHg nmHg  sto verl stimuli kg	bal stimuli Unres counds/our feet/inche	☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ State of the control of the contr	
13. Heart Rate 14. Systolic Blood Pressure 15. Diastolic Blood Pressure 16. Peripheral O <sub>2</sub> Saturation (SpO <sub>2</sub> 17. Glasgow Coma Score (out of 15 18. AVPU (tick state of consciousne) 19. Weight 20. Height 21. Weight loss If yes, specify lost during this of	s) or ess)	□ Ale □ Re □ Yes □ Cer □ Yes	tender to the control of the control	beats/mi nmHg nmHg 6 ls to verl stimuli kg	bal stimuli Unres counds/our feet/inche	☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ State of the state o	

(since mist day of onset of this inness episode)				
25. Amnesia	□Yes □No □Unknown			



## ZIKA VIRUS CASE REPORT FORMS – MATERNAL ACUTE SYMPTOMS – (MAS)





Mother's Identification Code: Neonate's Identification Code:					
26. Confusion/disorientation	□Yes □No □Unknown				
27. Altered behavior or personality	□Yes □No □Unknown				
28. Headache	☐Mild ☐Moderate ☐Severe ☐No ☐Unknown				
29. Photophobia	□Yes □No □Unknown				
30. Neck stiffness	□Yes □No □Unknown				
31. Seizures	☐General ☐Focal ☐No ☐Unknown				
32. Paralysis	□General □Ascending □No □Unknown				
If yes, describe affected body parts and if progress					
33. Weakness	☐General ☐Focal ☐No ☐Unknown				
	oPower test oPatient complaint				
If focal, please describe affected body parts and if	Fprogressive: □Yes □No				
34. Oromotor dysfunction	□Yes □No □Unknown				
35. Movement disorder	□Yes □No □Unknown				
36. Shortness of breath	□Yes □No □Unknown				
37. Sore throat	□Yes □No □Unknown				
38. Cough	□Yes □No □Unknown				
39. Rhinitis	□Yes □No □Unknown				
40. Chest pain	□Yes □No □Unknown				
41. Back pain	☐Yes ☐No ☐Unknown				
42. Myalgia	□Yes □No □Unknown				
43. Arthralgia	□Yes □No □Unknown				
44. Joint swelling	□Yes □No □Unknown				
If yes, specify all affected joints:	o Fingers o Toes o Knee o Elbow				
AF. Conjugativitie	o Other (specify):				
45. Conjunctivitis	☐Yes ☐No ☐Unknown				
If yes, specify if:	□Purulent □Non-purulent				
46. Retro-orbital pain	☐Yes ☐No ☐Unknown				
47. Periorbital pain	☐Yes ☐No ☐Unknown				
48. Rash	☐Yes ☐No ☐Unknown				
If yes, please check box for type of rash and specif	· T				
49. Maculopapular rash	☐Yes ☐No ☐Centrifugal ☐Centripetal Location:				
50. Erythematous rash	☐Yes ☐No ☐Centrifugal ☐Centripetal Location:				
51. Non blanching rash	☐Yes ☐No ☐Centrifugal ☐Centripetal				
	Location:				
52. Vesicular rash	☐Yes ☐No ☐Centrifugal ☐Centripetal Location:				
53. Erythema migrans	☐Yes ☐No ☐Centrifugal ☐Centripetal Location:				
54. Pruritic rash	☐Yes ☐No ☐Centrifugal ☐Centripetal Location:				
55. Petechial or purpuric rash	☐Yes ☐No ☐Centrifugal ☐Centripetal Location:				



Mother's Identification Code:

## ZIKA VIRUS CASE REPORT FORMS – MATERNAL ACUTE SYMPTOMS – (MAS)

Neonate's Identification Code : \_





56. Bruising/ ecchymosis		□Yes I	□No	□Centrifugal Location:	☐ Centripetal		
57. If other type of rash, ple	ase specify type and	Type:					
spread:			O Face O Torso O Upper limbs O Lower limbs O Palms				
		O Othe	r:				
58. Pruritus		□Yes I	□No □Ur	nknown			
If yes, specify:		□Gene	ralized $\Box$ L	.ocalized			
59. Jaundice		□Yes I	□No □Ur	nknown			
60. Sign of insect bites		□Yes I	□No □Ur	nknown			
61. Bleeding		□Yes I	□No □Ur	nknown			
If yes, please state source:			_	s O Nose O He	matemesis		
			na or fresh	•			
			aturia O Va	iginal			
C2 Marth plans			r, specify:				
62. Mouth ulcers			□No □Ur				
63. Diarrhea			□No □Ur				
64. Vomiting/nausea			□No □Ur				
65. Stomach pain		∟Yes I	□No □Ur	iknown			
66. Other (specify):							
3) MEDICATIONS ADMIN	JISTEPED (from onsot	of first s	mntoms of	this illness onice	do)		
			inplonis of	tilis lililess episc	lue)		
List all medications administ			his illnoss o	nicada fram date	of ansat		
Use generic names, list all tro			1				
Type of medication	Name of medication a	asob ba	Start da	to Number	Route of		
Type of medication	Name of medication a		Start da		Route of administration		
	Name of medication a (generic name		Start da (dd/mm/y		administration		
Type of medication  67. Antibiotics  □Yes □No							
67. Antibiotics  □Yes □No					administration □IV □Oral □IM		
67. Antibiotics					administration  □IV □Oral		
67. Antibiotics  Yes No  68. Antivirals  Yes No					administration  Oral  IM  Oral  Oral		
67. Antibiotics  □Yes □No  68. Antivirals					administration □IV □Oral □IM		
67. Antibiotics  Yes No  68. Antivirals  Yes No  69. Anti-inflammatories/ Antipyretics					administration  Oral  IM  Oral  Oral		
67. Antibiotics  Yes No  68. Antivirals  Yes No  69. Anti-inflammatories/					administration  Oral  IM  Oral  Oral		
67. Antibiotics  Yes No  68. Antivirals  Yes No  69. Anti-inflammatories/ Antipyretics  Yes No					administration  IV Oral IM IV Oral  IV Oral		
67. Antibiotics  Yes No  68. Antivirals  Yes No  69. Anti-inflammatories/ Antipyretics  Yes No  70. Corticosteroids					administration  IV Oral IM IV Oral  IV Oral		
67. Antibiotics  Yes No  68. Antivirals  Yes No  69. Anti-inflammatories/ Antipyretics  Yes No  70. Corticosteroids  Yes No					administration  IV Oral  IN Oral  IV Oral  IV Oral  IV Oral  IV Oral  IV Oral		
67. Antibiotics  Yes No  68. Antivirals  Yes No  69. Anti-inflammatories/ Antipyretics  Yes No  70. Corticosteroids  Yes No  71. Anticonvulsants  Yes No  72. Immunoglobulins					administration    IV		
67. Antibiotics  Yes No  68. Antivirals  Yes No  69. Anti-inflammatories/ Antipyretics  Yes No  70. Corticosteroids  Yes No  71. Anticonvulsants  Yes No  72. Immunoglobulins  Yes No					administration    IV		
67. Antibiotics  Yes No  68. Antivirals  Yes No  69. Anti-inflammatories/ Antipyretics  Yes No  70. Corticosteroids  Yes No  71. Anticonvulsants  Yes No  72. Immunoglobulins					administration    IV		
67. Antibiotics  Yes No  68. Antivirals  Yes No  69. Anti-inflammatories/ Antipyretics  Yes No  70. Corticosteroids  Yes No  71. Anticonvulsants  Yes No  72. Immunoglobulins  Yes No					administration    IV		
67. Antibiotics  Yes No  68. Antivirals  Yes No  69. Anti-inflammatories/ Antipyretics  Yes No  70. Corticosteroids  Yes No  71. Anticonvulsants  Yes No  72. Immunoglobulins  Yes No					administration    IV		
67. Antibiotics  Yes No  68. Antivirals  Yes No  69. Anti-inflammatories/ Antipyretics  Yes No  70. Corticosteroids  Yes No  71. Anticonvulsants  Yes No  72. Immunoglobulins  Yes No					administration    IV		
67. Antibiotics  Yes No  68. Antivirals  Yes No  69. Anti-inflammatories/ Antipyretics  Yes No  70. Corticosteroids  Yes No  71. Anticonvulsants  Yes No  72. Immunoglobulins  Yes No  73. Other (specify):					administration    IV		
67. Antibiotics  Yes No  68. Antivirals  Yes No  69. Anti-inflammatories/ Antipyretics  Yes No  70. Corticosteroids  Yes No  71. Anticonvulsants  Yes No  72. Immunoglobulins  Yes No					administration    IV		
67. Antibiotics  Yes No  68. Antivirals  Yes No  69. Anti-inflammatories/ Antipyretics  Yes No  70. Corticosteroids  Yes No  71. Anticonvulsants  Yes No  72. Immunoglobulins  Yes No  73. Other (specify):					administration    IV		
67. Antibiotics  Yes No  68. Antivirals  Yes No  69. Anti-inflammatories/ Antipyretics  Yes No  70. Corticosteroids  Yes No  71. Anticonvulsants  Yes No  72. Immunoglobulins  Yes No  73. Other (specify):					administration    IV		



# ZIKA VIRUS CASE REPORT FORMS – MATERNAL ACUTE SYMPTOMS – (MAS)





womer's identificatio	n code	Neonate	s identification code	•
				□Sublingual
Other (specify):				□IV □Oral
				☐Topical ☐Inhaled
				□Subcut □PR
				□м
				□Sublingual
Other (specify):				□IV □Oral
				☐Topical ☐Inhaled
				□Subcut □PR
				□м
				□Sublingual
4) TRANSFER TO	OTHER HOSPIT	AL		
74. Was the patient tra another hospital?	ansferred to	□Yes □No □Un	ıknown	
75. If yes, please state	name of the	Hospital name:		
hospital and city (addr	ess if possible)	City/Town/Village:		
76. Please state reasor	n for transfer:	-		
f patient was admitte	d to intensive care	, please also comple	ete the ZIKV CRF- Ma	ternal Intensive Care (MIC).
5) CASE REPORT F	FORM COMPLE	TED BY		
Name and role				
			<b>5</b> . (11/ / )	1
Signature			Date (dd/mm/yyyy)	